Published in
Elsevier, EBioMedicine, (97), p. 104842, 2023
DOI: 10.1016/j.ebiom.2023.104842
Links
Tools
Long-term safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2 in adults aged 18–55 years or ≥56 years: 12-month results from a randomised, double-blind, placebo-controlled, phase 1 trial
Journal article published in 2023 by
Keith J. Chappell 
,
Francesca L. Mordant,
Alberto A. Amarilla,
Naphak Modhiran,
Benjamin Liang ,
Zheyi Li,
Danushka K. Wijesundara,
Julia A. Lackenby ,
Paul Griffin,
Jillian K. Bennet,
Luca Hensen,
Wuji Zhang,
Thi H. O. Nguyen,
Mai H. Tran,
Peter Tapley
and other authors.
,
Francesca L. Mordant,
Alberto A. Amarilla,
Naphak Modhiran,
Benjamin Liang ,
Zheyi Li,
Danushka K. Wijesundara,
Julia A. Lackenby ,
Paul Griffin,
Jillian K. Bennet,
Luca Hensen,
Wuji Zhang,
Thi H. O. Nguyen,
Mai H. Tran,
Peter Tapley
and other authors.
This paper is made freely available by the publisher.
Full text: Download
Postprint:
archiving forbidden
Data provided by 